← FDA DRUG APPROVALS

FDA NDA · NDA212121

POTASSIUM PHOSPHATES

Sponsor: CMP DEV LLC

APPLICATION
NDA212121
TYPE
NDA
ORIGINAL APPROVAL
2019-09-19
LATEST ACTION
2019-09-19
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Discontinued

Products

POTASSIUM PHOSPHATES · ReferenceDiscontinued
POTASSIUM PHOSPHATE, DIBASIC 4.5GM/15ML (300MG/ML), POTASSIUM PHOSPHATE, MONOBASIC 2.65GM/15ML (175MG/ML) · SOLUTION · INTRAVENOUS

Approval history

2019-09-19Type 5 - New Formulation or New Manufacturer · Original · priority — Label ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →